<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Staging investigations in the Malawi 2003 BL protocol included abdominal ultrasonography </plain></SENT>
<SENT sid="1" pm="."><plain>This sometimes demonstrated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> that was not palpable </plain></SENT>
<SENT sid="2" pm="."><plain>Patients with no palpable <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> following induction with three courses of <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> were considered to be in remission, although residual intraabdominal <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> was documented in some by chance </plain></SENT>
<SENT sid="3" pm="."><plain>We repeated ultrasonography on day 29 on 22 new patients with non-palpable abdominal <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> following induction </plain></SENT>
<SENT sid="4" pm="."><plain>The relapse rate after 1 year correlated with the largest <z:e sem="disease" ids="C0543478" disease_type="Neoplastic Process" abbrv="">residual tumor</z:e> volume, and was 17% for <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> 0-35 ml, and 75% for <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> &gt; or = 35 ml in volume </plain></SENT>
<SENT sid="5" pm="."><plain>Risk patients were thus identified </plain></SENT>
</text></document>